Medtronic Debuts Medical Device in U.S. Designed to Improve Treatment of Aortic Aneurysms
Medtronic has announced the U.S. launch of the Talent Abdominal Stent Graft on the Xcelerant Hydro Delivery System. EVAR is a treatment for aortic aneurysm, a bulge or weakening in the body’s main artery that can rupture with fatal consequences if left untreated. EVAR involves the navigation of a stent graft, via the body’s arteries, to the aorta. The stent graft is then deployed to create a tube within the aorta, reducing pressure on the aneurysm and the risk of rupture. EVAR is a minimally-invasive alternative to open surgical repair.

The U. S. Food and Drug Administration has granted approval to
The U.S. Food and Drug Administration has approved PMA supplement for
The U.S Food and Drug Administration (FDA) has given an unconditional Investigational Device Exemption to
The U.S. Food and Drug Administration has cleared
The U.S. Food and Drug Administration has granted clearance to
The U.S. Food and Drug Administration has approved the commercialization of 
The US Food and Drug Administration (FDA) has broadened the approval to W. L. Gore & Associates for its